Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Italian Stock Exchange  >  Recordati    REC   IT0003828271

RECORDATI (REC)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 06/18 11:35:50 am
32.57 EUR   -0.85%
06/11RECORDATI : Acquires natural point s.r.l. in italy
GL
05/17EXCLUSIVE - CVC : sources
RE
05/08RECORDATI : Announces sales and margin growth in the first quarter 2..
GL
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   End-of-day quote. End-of-day quote Italian Stock Exchange
06/11/2018 06/12/2018 06/13/2018 06/14/2018 06/15/2018 Date
32.77(c) 32.84(c) 32.92(c) 33.3(c) 32.85(c) Last
637 585 471 390 427 042 515 462 1 003 169 Volume
+0.68% +0.21% +0.24% +1.15% -1.35% Change
More quotes
Financials (EUR)
Sales 2018 1 370 M
EBIT 2018 438 M
Net income 2018 312 M
Debt 2018 331 M
Yield 2018 2,76%
Sales 2019 1 434 M
EBIT 2019 462 M
Net income 2019 332 M
Debt 2019 196 M
Yield 2019 2,90%
P/E ratio 2018 21,88
P/E ratio 2019 20,61
EV / Sales2018 5,26x
EV / Sales2019 4,93x
Capitalization 6 870 M
More Financials
Company
Recordati SpA engages in the research, development, manufacturing and marketing of pharmaceuticals.It operates through two segments: Pharmaceutical and Rare Diseases.The Pharmaceutical segment offers prescription and over-the-counter products as well as chemical syntheses, intermediates, and active... 
Sector
Pharmaceuticals
Calendar
07/26Earnings Release
More about the company
Surperformance© ratings of Recordati
Trading Rating : Investor Rating :
More Ratings
Latest news on RECORDATI
06/11RECORDATI : Acquires natural point s.r.l. in italy
GL
05/17EXCLUSIVE - CVC PUTS $9 BILLION RECO : sources
RE
05/08RECORDATI : Announces sales and margin growth in the first quarter 2018. revenue..
GL
04/23RECORDATI : Ex-dividend day for final dividend
FA
04/18RECORDATI : Press Release
CO
04/09RECORDATI : Acquires international rights to cystagon® from mylan
GL
03/15RECORDATI : Board approves the 2017 accounts. sales € 1,288.1 million (+11.6%),..
GL
02/14RECORDATI : Regent Pacific says Fortacin officially launched in Europe
AQ
02/08RECORDATI : Preliminary 2017 results confirm continued growth of sales and profi..
GL
02/08RECORDATI : Preliminary 2017 results confirm continued growth of sales and profi..
GL
More news
Sector news : Pharmaceuticals - NEC
02:51aINDIVIOR : Wins Legal Battle; Temporarily Blocks Launch of Generic Drug
DJ
02:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/16International fund managers turn to financials, tech as trade worries rise
RE
06/15BAYER : Japan suspends sale of Canadian wheat after GMO wheat found in Alberta
RE
06/15UK's Indivior will fight U.S. FDA's approval for copycat drug
RE
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on RECORDATI 
RECORDATI - 01/22
In an accumulation phase
BUY
RECORDATI SPA - 2016
A medium term support level to take advantage of
BUY
More Strategies
Latest Tweets
06/11Recordati acquires Natural Point S.R.L.  
06/11RECORDATI ACQUIRES NATURAL POINT S.R.L. IN ITALY  
05/17Exclusive: CVC puts $9 billion Recordati bid on hold as political uncertainty..
1
05/16CVC puts $9 billion Recordati bid on hold as political uncertainty weighs: Re.. 
05/16Exclusive: CVC puts $9 billion Recordati bid on hold as political uncertainty..
2
More tweets
Qtime:17
News from SeekingAlpha
06/11Recordati acquires Natural Point S.R.L. 
06/07Recordati (RCDTF) Presents At Jefferies 2018 Global Healthcare Conference - S.. 
05/24RECORDATI : A Somehow Boring But Interesting Pharmaceutical Company 
05/08Recordati Industria Chimica e Farmaceutica reports Q1 results 
02/08Recordati Industria Chimica e Farmaceutica reports FY results 
Chart RECORDATI
Duration : Period :
Recordati Technical Analysis Chart | REC | IT0003828271 | 4-Traders
Technical analysis trends RECORDATI
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 35,6 €
Spread / Average Target 8,3%
EPS Revisions
Managers
NameTitle
Andrea Recordati Vice Chairman & Chief Executive Officer
Alberto Recordati Chairman
Fritz Squindo Chief Financial Officer, Executive Director & MD
Mario Garraffo Independent Non-Executive Director
Marco Vitale Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
RECORDATI-11.36%7 975
JOHNSON & JOHNSON-12.21%328 858
PFIZER-0.17%212 690
NOVARTIS-8.25%193 446
ROCHE HOLDING LTD.-14.06%183 969
MERCK AND COMPANY10.24%166 880